AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18632838 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated without extraction of teeth
Number of subjects: 68
Study 18632838 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects treated with extractions
Number of subjects: 68
Study 17128523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 0
Study 17128523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12755838 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative transarterial chemotherapy
Number of subjects: 0
Study 10993855 — intervention group
Group type: EXPERIMENTAL
Intervention: US intervention (angiography and revascularization)
Number of subjects: 3172
Study 10993855 — intervention group
Group type: COMPARATOR
Intervention: Canadian intervention (noninvasive stress testing)
Number of subjects: 3172
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: ICUs with more than 600 beds
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous catheters
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheterisation of the urinary tract
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheters
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric tubes
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drainage
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial ventilation
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine microbiological surveillance of tracheal aspirates
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine microbiological surveillance of urine
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily changing of ventilation tubes
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion sets changed daily
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs for the prevention of stress ulcers
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate for stress ulcer prevention
Number of subjects: 515
Study 9065253 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract
Number of subjects: 515
Study 2003537 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational preterm delivery prevention program
Number of subjects: 394
Study 2003537 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program + Home uterine monitoring
Number of subjects: 394
Study 2003537 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar high-risk patients who did not participate in these programs)
Number of subjects: 394
Study 6148312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol (1-4 mg once daily)
Number of subjects: 17
Study 6148312 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40-120 mg t.i.d.)
Number of subjects: 17
Study 28082277 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative medical and chiropractic care with interprofessional education, clinical record exchange, and team‐based case management
Number of subjects: 19
Study 28082277 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent medical and chiropractic care
Number of subjects: 19
Study 28082277 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 19
Study 27644138 — intervention group
Group type: EXPERIMENTAL
Intervention: ε-caprolactam concentration of 0.05 mg/m³
Number of subjects: 52
Study 27644138 — intervention group
Group type: EXPERIMENTAL
Intervention: ε-caprolactam concentration of 0.5 mg/m³
Number of subjects: 52
Study 27644138 — intervention group
Group type: EXPERIMENTAL
Intervention: ε-caprolactam concentration of 5.0 mg/m³
Number of subjects: 52
Study 27644138 — intervention group
Group type: COMPARATOR
Intervention: Control condition (0.0 mg/m³)
Number of subjects: 52
Study 25008901 — intervention group
Group type: EXPERIMENTAL
Intervention: Early booster (9 to 12 months)
Number of subjects: 256
Study 25008901 — intervention group
Group type: EXPERIMENTAL
Intervention: Late booster (15 to 18 months)
Number of subjects: 256
Study 25008901 — intervention group
Group type: EXPERIMENTAL
Intervention: Catch-up vaccination (2 doses plus experimental booster)
Number of subjects: 256
Study 25008901 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events in early booster group
Number of subjects: 256
Study 25008901 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events in catch-up group
Number of subjects: 256
Study 22181026 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy (ABFT)
Number of subjects: 10
Study 20044704 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming group (n = 11)
Number of subjects: 22
Study 20044704 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 22
Study 20044704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 19123874 — intervention group
Group type: EXPERIMENTAL
Intervention: Shirodhara treatment
Number of subjects: 32
Study 19123874 — intervention group
Group type: COMPARATOR
Intervention: Control position
Number of subjects: 32
Study 15927409 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate concurrent chemoradiation (cisplatin-based) with short overall treatment time (completed within 5 days of plan)
Number of subjects: 474
Study 15927409 — intervention group
Group type: COMPARATOR
Intervention: Immediate concurrent chemoradiation (cisplatin-based) with prolonged treatment time (protocol violation)
Number of subjects: 474
Study 15927409 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment time as a continuous variable
Number of subjects: 474
Study 15927409 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate concurrent chemoradiation (cisplatin-based)
Number of subjects: 474
Study 15478385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 2000 microg/d via a 750-mL primed spacer for 2 weeks
Number of subjects: 20
Study 11506515 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacron grafts
Number of subjects: 194
Study 11506515 — intervention group
Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 194
Study 9247510 — intervention group
Group type: COMPARATOR
Intervention: 400 IU of vitamin E, 500 mg of vitamin C, 12 mg of beta-carotene (mid-dose)
Number of subjects: 45
Study 9247510 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU of vitamin E, 1,000 mg of vitamin C, 24 mg of beta-carotene (high dose)
Number of subjects: 45
Study 9247510 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 45
Study 8391566 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 41
Study 8391566 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 41
Study 8391566 — intervention group
Group type: COMPARATOR
Intervention: Bottle-weight measure
Number of subjects: 41
Study 8391566 — intervention group
Group type: COMPARATOR
Intervention: Urine bioassay
Number of subjects: 41
Study 8391566 — intervention group
Group type: COMPARATOR
Intervention: Parent report diary
Number of subjects: 41
Study 3552460 — intervention group
Group type: EXPERIMENTAL
Intervention: 10/10/10 micrograms HA formulation
Number of subjects: 120
Study 3552460 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent A/Singapore/6/86-like vaccine
Number of subjects: 120
Study 3552460 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent A/Mississippi, A/Chile, B/Ann Arbor influenza vaccine
Number of subjects: 120
Study 3552460 — intervention group
Group type: EXPERIMENTAL
Intervention: A/Singapore vaccine
Number of subjects: 120
Study 29436348 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored food samples
Number of subjects: 182
Study 29436348 — intervention group
Group type: EXPERIMENTAL
Intervention: Flies captured in households
Number of subjects: 182
Study 29436348 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired fly-food samples
Number of subjects: 182
Study 27840374 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (LA) treatment
Number of subjects: 100
Study 27840374 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 100
Study 24411718 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 polyunsaturated fatty acids (1.14g DHA and 1.56g EPA)
Number of subjects: 20
Study 24152081 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Led Activity and Nutrition for Healthy Living weight management program (10-week duration, including two motivational interviewing visits, four group sessions, and four phone follow-ups)
Number of subjects: 67
Study 24152081 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 67
Study 20846018 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored cardiac rehabilitation program with motivational interviewing guided by the Transtheoretical Model (TTM)
Number of subjects: 225
Study 20846018 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation program
Number of subjects: 225
Study 18553032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125% (15 ml)
Number of subjects: 32
Study 18553032 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.0625% plus 75 microg clonidine (15 ml)
Number of subjects: 32
Study 16651056 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose warfarin (mean INR 1.4, goal INR <2.0)
Number of subjects: 1244
Study 16651056 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intake categories (non-, light, moderate, heavier drinkers)
Number of subjects: 1244
Study 12816770 — intervention group
Group type: COMPARATOR
Intervention: L-MUFA (7.8% of energy from MUFAs)
Number of subjects: 35
Study 12816770 — intervention group
Group type: EXPERIMENTAL
Intervention: M-MUFA (10.3% of energy from MUFAs)
Number of subjects: 35
Study 12816770 — intervention group
Group type: EXPERIMENTAL
Intervention: H-MUFA (13.7% of energy from MUFAs)
Number of subjects: 35
Study 10853566 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine administered preoperatively
Number of subjects: 0
Study 7756096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg once daily for 8 days
Number of subjects: 16
Study 7756096 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2 mg single dose
Number of subjects: 16
Study 7756096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2312774 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/ZOK 100-200 mg daily
Number of subjects: 0
Study 2312774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 156006 — intervention group
Group type: EXPERIMENTAL
Intervention: Grading system for acne severity on a zero to eight scale anchored to photographic standards.
Number of subjects: 0
Study 30346364 — intervention group
Group type: EXPERIMENTAL
Intervention: Study invitation placed early within discharge instructions (DCIs)
Number of subjects: 963
Study 30346364 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 963
Study 30346364 — intervention group
Group type: EXPERIMENTAL
Intervention: Laceration diagnosis
Number of subjects: 963
Study 30346364 — intervention group
Group type: COMPARATOR
Intervention: Parents of Hispanic children
Number of subjects: 963
Study 31989459 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed breast milk
Number of subjects: 45
Study 31989459 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose solution
Number of subjects: 45
Study 31989459 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 45
Study 29390915 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion site failure detection algorithm
Number of subjects: 19
Study 29390915 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) arm
Number of subjects: 19
Study 27444763 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical local anesthesia combined with sedation (group LA + S; n = 76)
Number of subjects: 153
Study 27444763 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (group GA; n = 77)
Number of subjects: 153
Study 23987833 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin as second-line treatment (24-hour infusion every 3 weeks)
Number of subjects: 129
Study 22534669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m²) + Cisplatin (75 mg/m²) followed by Gefitinib (250 mg/d)
Number of subjects: 70
Study 22534669 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed (500 mg/m²) + Cisplatin (75 mg/m²) followed by Pemetrexed (500 mg/m²)
Number of subjects: 70
Study 20126965 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Trained Creatine (RTCr, 5g Cr)
Number of subjects: 42
Study 20126965 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Trained Protein (RTPr, 35g whey Pr)
Number of subjects: 42
Study 20126965 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Trained Creatine and Protein (RTCrPr, 5g Cr and 35g Pr)
Number of subjects: 42
Study 20126965 — intervention group
Group type: COMPARATOR
Intervention: Resistance Trained Placebo (RTP)
Number of subjects: 42
Study 18082920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at two different cadences
Number of subjects: 20
Study 15671124 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg on days 1-8, 40 mg on days 8-15)
Number of subjects: 24
Study 15671124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg on days 1-8, 100 mg on days 8-15)
Number of subjects: 24
Study 15671124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12952837 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CHF
Number of subjects: 21
Study 10494365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10494365 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (0.3 mg x kg‐1)
Number of subjects: 120
Study 10494365 — intervention group
Group type: COMPARATOR
Intervention: Dimenhydrinate (1 mg x kg‐1)
Number of subjects: 120
Study 10494365 — intervention group
Group type: COMPARATOR
Intervention: Combination of dimenhydrinate (1 mg x kg‐1) and metoclopramide (0.3 mg x kg‐1)
Number of subjects: 120
Study 9005795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg once a day for medium urinary tract infections
Number of subjects: 30
Study 9005795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 100 mg twice a day for 3 to 7 days for severe lower urinary tract infections
Number of subjects: 30
Study 9005795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg twice a day for 7 to 10 days for severe upper urinary tract infections
Number of subjects: 30
Study 9005795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 50 mg once a day for 6 months for frequent acute recurring infections
Number of subjects: 30
Study 9005795 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (various regimens)
Number of subjects: 30
Study 2073484 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% lidocaine hydrocarbonate (CO2) with 1:200,000 epinephrine
Number of subjects: 50
Study 2073484 — intervention group
Group type: COMPARATOR
Intervention: 1.0% lidocaine hydrochloride (HCl) with 1:200,000 epinephrine
Number of subjects: 50
Study 2073484 — intervention group
Group type: COMPARATOR
Intervention: lidocaine HCl
Number of subjects: 50
Study 2073484 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine CO2
Number of subjects: 50
Study 6788406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg twice daily, orally)
Number of subjects: 64
Study 6788406 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (inhalation of 20 mg, four times daily)
Number of subjects: 64
Study 6788406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 6788406 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 64
Study 6366148 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug program (cyclophosphamide, vincristine, methotrexate, prednisone [COMP])
Number of subjects: 73
Study 6366148 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-drug program (LSA2-L2 modified)
Number of subjects: 73
Study 6366148 — intervention group
Group type: EXPERIMENTAL
Intervention: COMP
Number of subjects: 73
Study 6366148 — intervention group
Group type: EXPERIMENTAL
Intervention: LSA2-L2
Number of subjects: 73
Study 6366148 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both treatments)
Number of subjects: 73
Study 6366148 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (adverse events)
Number of subjects: 73
Study 30589654 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Training (ST) group
Number of subjects: 40
Study 30589654 — intervention group
Group type: COMPARATOR
Intervention: Traditional Training (TT) group
Number of subjects: 40
Study 28916891 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop-tip guidewire (LGW)
Number of subjects: 192
Study 28916891 — intervention group
Group type: COMPARATOR
Intervention: Straight-tip guidewire (SGW)
Number of subjects: 192
Study 27399527 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 351
Study 27399527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 24646343 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS group (n=56)
Number of subjects: 161
Study 24646343 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-SMS group (n=48)
Number of subjects: 161
Study 24646343 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=57)
Number of subjects: 161
Study 22975616 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (5 cycles of fluorouracil and leucovorin)
Number of subjects: 90
Study 22975616 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation therapy (1 cycle of FL, then 45 Gy radiation concurrently with 2 cycles of FL, followed by 2 cycles of FL)
Number of subjects: 90
Study 19460762 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfrey root extract ointment (4 g per application, three times a day)
Number of subjects: 120
Study 19460762 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment (4 g per application, three times a day)
Number of subjects: 120
Study 19460762 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfrey root extract ointment
Number of subjects: 120
Study 17914338 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent discussion with illustrated flip chart
Number of subjects: 122
Study 17914338 — intervention group
Group type: COMPARATOR
Intervention: Usual care consent process (without flip chart)
Number of subjects: 122
Study 16037704 — intervention group
Group type: EXPERIMENTAL
Intervention: Midnight removal of catheter (ROC)
Number of subjects: 84
Study 16037704 — intervention group
Group type: COMPARATOR
Intervention: Early morning removal of catheter (ROC)
Number of subjects: 84
Study 12025737 — intervention group
Group type: EXPERIMENTAL
Intervention: Photic stimulation (PS)
Number of subjects: 0
Study 10025472 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (100 mg daily) and Vitamin C (500 mg daily) for 15 weeks
Number of subjects: 38
Study 10025472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7789200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociometrically neglected children
Number of subjects: 423
Study 7789200 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive-rejected children
Number of subjects: 423
Study 7789200 — intervention group
Group type: EXPERIMENTAL
Intervention: Submissive-rejected children
Number of subjects: 423
Study 7789200 — intervention group
Group type: COMPARATOR
Intervention: Average status children
Number of subjects: 423
Study 2347518 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin at very ultra low dosage
Number of subjects: 20
Study 373517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized atropine sulfate
Number of subjects: 13
Study 373517 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 13
Study 373517 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nebulized atropine sulfate and isoproterenol
Number of subjects: 13
Study 373517 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol alone
Number of subjects: 13
Study 31242065 — intervention group
Group type: EXPERIMENTAL
Intervention: Livelihood intervention
Number of subjects: 54
Study 31242065 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 31209815 — intervention group
Group type: EXPERIMENTAL
Intervention: PPOS protocol
Number of subjects: 157
Study 31209815 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 157
Study 27623133 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMV + VG
Number of subjects: 34
Study 27623133 — intervention group
Group type: COMPARATOR
Intervention: PSV + VG
Number of subjects: 34
Study 25746779 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography
Number of subjects: 18840
Study 25746779 — intervention group
Group type: COMPARATOR
Intervention: Single-view chest radiography
Number of subjects: 18840
Study 25746779 — intervention group
Group type: EXPERIMENTAL
Intervention: False positive screening results
Number of subjects: 18840
Study 23904337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam (0.1 mg/kg, n = 234)
Number of subjects: 436
Study 23904337 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal diazepam (0.5 mg/kg, n = 202)
Number of subjects: 436
Study 23904337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam
Number of subjects: 436
Study 23904337 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal diazepam
Number of subjects: 436
Study 21903893 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (titrated to 250 mg daily in the morning)
Number of subjects: 37
Study 21903893 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine alone
Number of subjects: 37